LFCR
Lifecore Biomedical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.40
+1.15%Income statement
| Metric | TTM | 2026 | 2025 | 2025 | 2024 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 125.7M | 34.2M | 129.5M | 128.9M | 128.3M |
| Cost of Revenue | 85.0M | 22.1M | 88.9M | 88.6M | 86.4M |
| Gross Profit | 40.7M | 12.1M | 40.6M | 40.3M | 41.9M |
| Operating Expenses | |||||
| R&D Expense | 5.8M | 1.5M | 8.5M | 8.3M | 8.6M |
| SG&A Expense | 31.8M | 8.0M | 33.4M | 44.0M | 40.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 8.4K | 5.2M | 1.7M |
| Total Operating Expenses | 37.7M | 9.5M | 41.9M | 57.5M | 50.7M |
| Cost and Expenses | 122.7M | 31.6M | 130.7M | 146.1M | 137.1M |
| Operating Income (EBIT) | 3.0M | 2.6M | (1.3M) | (17.2M) | (8.8M) |
| Non-Operating | |||||
| Interest Income | 560.0K | 144.0K | — | — | — |
| Interest Expense | 30.6M | 7.7M | (2.2M) | 21.8M | 18.1M |
| Net Interest Income | (30.0M) | (7.6M) | (26.7M) | (21.8M) | (18.1M) |
| Other Non-Op Income/Expense | (36.4M) | (8.7M) | (29.0M) | (21.4M) | 18.4M |
| Non-Operating Income (excl Interest) | 5.8M | 1.0M | — | (406.0K) | (36.4M) |
| EBT (Pre-Tax Income) | (33.3M) | (6.1M) | (30.2M) | (38.7M) | 9.5M |
| Income Tax Expense | 112.0K | 23.0K | 577.7K | 43.0K | 183.0K |
| Bottom Line | |||||
| Net Income | (33.4M) | (6.2M) | (30.8M) | (38.7M) | 12.0M |
| Earnings from Cont. Ops | (33.4M) | (6.2M) | (30.8M) | (38.7M) | 9.3M |
| Earnings from Discont. Ops | — | — | — | — | 2.7M |
| Bottom Line Net Income | (37.3M) | (7.1M) | (34.5M) | (44.4M) | 12.0M |
| Per Share | |||||
| Basic EPS | ($1.00) | ($0.19) | ($0.92) | ($1.27) | $0.39 |
| Diluted EPS | ($1.00) | ($0.19) | ($0.93) | ($1.27) | $0.33 |
| Revenue Per Share | $3.35 | $0.91 | $3.89 | $3.70 | $4.21 |
| Shares | |||||
| Basic Shares Outstanding | 37.6M | 37.6M | 33.3M | 34.8M | 30.5M |
| Diluted Shares Outstanding | 37.6M | 37.6M | 37.4M | 34.8M | 36.7M |
| Profitability Metrics | |||||
| EBITDA | 7.1M | 6.4M | 8.2M | (8.8M) | 35.6M |
| D&A | 9.9M | 4.8M | 9.5M | 8.0M | 8.0M |
| EBIT | (2.7M) | 1.6M | (1.3M) | (16.8M) | 27.6M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2026